iView Therapeutics key facts
as of Oct 2026- Developer of topical drugs designed for applications in ophthalmology, dermatology, and otolaryngology.
- iView Therapeutics is valued at approximately $107.4M as of Oct 2026, set at its later-stage round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $39.2M across 2 recorded rounds; the latest was Early Stage VC ($9.2M) in May 2024.
- Notable investors include Cowin Capital, Proxima Ventures (China), BioAdvance Capital (Conshohocken), Alpha Bioventure, Chongqing Dian Petrochemical Medical Fund Management — 16 tracked in total.
- iView Therapeutics has filed 4 Form Ds with the SEC since 2022, most recently Jun 2025 ($9.2M sold to 5 investors).
- Status: Privately Held (backing).
Valued at $107.4M at its later-stage round, Jun 2025. Nothing has traded since.
- ·The complete investor list: 16 names
- ·Watch iView Therapeutics: the Monday email on marks, rounds and moves
iView Therapeutics funding rounds
2 roundsWho backs iView Therapeutics
16+Membership and data by Private Market View
iView Therapeutics valuation
iView Therapeutics was valued at $107 million at its later-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has iView Therapeutics raised?
iView Therapeutics has raised $39.2 million across 2 recorded rounds since 2021. The largest was a $9.2 million early-stage round in May 2024.
iView Therapeutics has filed 4 Form Ds with the SEC since 2022, most recently in Jun 2025 ($9.2 million sold to 5 investors).
iView Therapeutics investors
16 investors are on record for iView Therapeutics, including Cowin Capital, Proxima Ventures (China), BioAdvance Capital (Conshohocken) and Alpha Bioventure. The early-stage round in May 2024 drew 5 investors.
About iView Therapeutics
Developer of topical drugs designed for applications in ophthalmology, dermatology, and otolaryngology. The company develops drugs including long-acting povidone-iodine ophthalmic formulations for the treatment of active infections of the conjunctiva and cornea, enabling the medical community to combat anti-viral and antimicrobial conditions effectively.
- Sector
- Healthcare
- HQ
- Cranbury, NJ, United States
- Founded
- 2015
- Employees
- 11
- Website
- iviewtherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.